CA3223669A1 - Sequencage simultane de brins complementaires sens et antisens sur des polynucleotides concatenes pour la detection de methylation - Google Patents
Sequencage simultane de brins complementaires sens et antisens sur des polynucleotides concatenes pour la detection de methylation Download PDFInfo
- Publication number
- CA3223669A1 CA3223669A1 CA3223669A CA3223669A CA3223669A1 CA 3223669 A1 CA3223669 A1 CA 3223669A1 CA 3223669 A CA3223669 A CA 3223669A CA 3223669 A CA3223669 A CA 3223669A CA 3223669 A1 CA3223669 A1 CA 3223669A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- sequencing
- complement
- polynucleotide
- signal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091033319 polynucleotide Proteins 0.000 title claims description 276
- 102000040430 polynucleotide Human genes 0.000 title claims description 276
- 239000002157 polynucleotide Substances 0.000 title claims description 276
- 238000012163 sequencing technique Methods 0.000 title claims description 263
- 230000000295 complement effect Effects 0.000 title claims description 227
- 230000002441 reversible effect Effects 0.000 title claims description 78
- 238000001514 detection method Methods 0.000 title claims description 38
- 230000011987 methylation Effects 0.000 title description 7
- 238000007069 methylation reaction Methods 0.000 title description 7
- 238000000034 method Methods 0.000 claims abstract description 206
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 26
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 170
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 142
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 133
- 230000027455 binding Effects 0.000 claims description 126
- 238000006243 chemical reaction Methods 0.000 claims description 106
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 claims description 85
- 229940035893 uracil Drugs 0.000 claims description 85
- 239000003795 chemical substances by application Substances 0.000 claims description 80
- 239000012634 fragment Substances 0.000 claims description 71
- 229940113082 thymine Drugs 0.000 claims description 71
- FHSISDGOVSHJRW-UHFFFAOYSA-N 5-formylcytosine Chemical compound NC1=NC(=O)NC=C1C=O FHSISDGOVSHJRW-UHFFFAOYSA-N 0.000 claims description 54
- 238000006481 deamination reaction Methods 0.000 claims description 54
- 101000964378 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3A Proteins 0.000 claims description 52
- 108010031325 Cytidine deaminase Proteins 0.000 claims description 51
- 102100040263 DNA dC->dU-editing enzyme APOBEC-3A Human genes 0.000 claims description 49
- 102100026846 Cytidine deaminase Human genes 0.000 claims description 47
- 230000009615 deamination Effects 0.000 claims description 46
- 239000007787 solid Substances 0.000 claims description 42
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 40
- 238000009396 hybridization Methods 0.000 claims description 37
- 230000003321 amplification Effects 0.000 claims description 36
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 36
- 239000002243 precursor Substances 0.000 claims description 36
- BLQMCTXZEMGOJM-UHFFFAOYSA-N 5-carboxycytosine Chemical compound NC=1NC(=O)N=CC=1C(O)=O BLQMCTXZEMGOJM-UHFFFAOYSA-N 0.000 claims description 34
- 239000003153 chemical reaction reagent Substances 0.000 claims description 33
- 238000012545 processing Methods 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 26
- 102000004190 Enzymes Human genes 0.000 claims description 23
- 108090000790 Enzymes Proteins 0.000 claims description 23
- 239000003638 chemical reducing agent Substances 0.000 claims description 22
- 229930024421 Adenine Natural products 0.000 claims description 20
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 20
- 229960000643 adenine Drugs 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 239000013043 chemical agent Substances 0.000 claims description 18
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 claims description 17
- 239000007800 oxidant agent Substances 0.000 claims description 17
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 14
- 229910052796 boron Inorganic materials 0.000 claims description 14
- 230000000903 blocking effect Effects 0.000 claims description 13
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 12
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 11
- 230000004048 modification Effects 0.000 claims description 11
- 238000012986 modification Methods 0.000 claims description 11
- 108030004080 Methylcytosine dioxygenases Proteins 0.000 claims description 10
- 238000004590 computer program Methods 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 10
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 claims description 9
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 claims description 9
- 101000653360 Homo sapiens Methylcytosine dioxygenase TET1 Proteins 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 238000000137 annealing Methods 0.000 claims description 7
- 238000007841 sequencing by ligation Methods 0.000 claims description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 6
- 229910000085 borane Inorganic materials 0.000 claims description 6
- 230000005945 translocation Effects 0.000 claims description 6
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 6
- 108010004483 APOBEC-3G Deaminase Proteins 0.000 claims description 5
- 102100040399 C->U-editing enzyme APOBEC-2 Human genes 0.000 claims description 5
- 102100040262 DNA dC->dU-editing enzyme APOBEC-3B Human genes 0.000 claims description 5
- 102100040261 DNA dC->dU-editing enzyme APOBEC-3C Human genes 0.000 claims description 5
- 102100040264 DNA dC->dU-editing enzyme APOBEC-3D Human genes 0.000 claims description 5
- 102100040266 DNA dC->dU-editing enzyme APOBEC-3F Human genes 0.000 claims description 5
- 102100038076 DNA dC->dU-editing enzyme APOBEC-3G Human genes 0.000 claims description 5
- 102100038050 DNA dC->dU-editing enzyme APOBEC-3H Human genes 0.000 claims description 5
- 101710082737 DNA dC->dU-editing enzyme APOBEC-3H Proteins 0.000 claims description 5
- 101000964322 Homo sapiens C->U-editing enzyme APOBEC-2 Proteins 0.000 claims description 5
- 101000964385 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3B Proteins 0.000 claims description 5
- 101000964383 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3C Proteins 0.000 claims description 5
- 101000964382 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3D Proteins 0.000 claims description 5
- 101000964377 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3F Proteins 0.000 claims description 5
- 101000800426 Homo sapiens Putative C->U-editing enzyme APOBEC-4 Proteins 0.000 claims description 5
- 102100033091 Putative C->U-editing enzyme APOBEC-4 Human genes 0.000 claims description 5
- QHXLIQMGIGEHJP-UHFFFAOYSA-N boron;2-methylpyridine Chemical compound [B].CC1=CC=CC=N1 QHXLIQMGIGEHJP-UHFFFAOYSA-N 0.000 claims description 5
- 229940104302 cytosine Drugs 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 102000051366 Glycosyltransferases Human genes 0.000 claims description 4
- 108700023372 Glycosyltransferases Proteins 0.000 claims description 4
- 101000653369 Homo sapiens Methylcytosine dioxygenase TET3 Proteins 0.000 claims description 4
- 102100030812 Methylcytosine dioxygenase TET3 Human genes 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 4
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 4
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- JYHRLWMNMMXIHF-UHFFFAOYSA-N (tert-butylamino)boron Chemical compound [B]NC(C)(C)C JYHRLWMNMMXIHF-UHFFFAOYSA-N 0.000 claims description 3
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 claims description 3
- 102100040397 C->U-editing enzyme APOBEC-1 Human genes 0.000 claims description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 3
- JBANFLSTOJPTFW-UHFFFAOYSA-N azane;boron Chemical compound [B].N JBANFLSTOJPTFW-UHFFFAOYSA-N 0.000 claims description 3
- QELVBRYVPXJQMT-UHFFFAOYSA-N boron;ethane-1,2-diamine Chemical compound [B].NCCN QELVBRYVPXJQMT-UHFFFAOYSA-N 0.000 claims description 3
- RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 claims description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 3
- 229910052707 ruthenium Inorganic materials 0.000 claims description 3
- 229910052723 transition metal Inorganic materials 0.000 claims description 3
- 150000003624 transition metals Chemical class 0.000 claims description 3
- 102100030819 Methylcytosine dioxygenase TET1 Human genes 0.000 claims description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 2
- 239000002585 base Substances 0.000 description 137
- 125000003729 nucleotide group Chemical group 0.000 description 54
- 239000002773 nucleotide Substances 0.000 description 47
- 230000008569 process Effects 0.000 description 31
- 239000011324 bead Substances 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 26
- 238000009826 distribution Methods 0.000 description 21
- 239000000758 substrate Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 18
- -1 triethylsilyl Chemical group 0.000 description 17
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 230000003647 oxidation Effects 0.000 description 14
- 238000007254 oxidation reaction Methods 0.000 description 14
- 239000000872 buffer Substances 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000013507 mapping Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 102000008300 Mutant Proteins Human genes 0.000 description 8
- 108010021466 Mutant Proteins Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 238000001369 bisulfite sequencing Methods 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 238000005286 illumination Methods 0.000 description 7
- 238000003672 processing method Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 241001515965 unidentified phage Species 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 102000000340 Glucosyltransferases Human genes 0.000 description 5
- 108010055629 Glucosyltransferases Proteins 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 125000003147 glycosyl group Chemical group 0.000 description 5
- 150000002923 oximes Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000012536 storage buffer Substances 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- POQQFTOTXNRFIL-UHFFFAOYSA-N (2-oxo-1h-pyrimidin-6-yl)carbamic acid Chemical compound OC(=O)NC1=CC=NC(=O)N1 POQQFTOTXNRFIL-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 4
- 102000005381 Cytidine Deaminase Human genes 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 150000003839 salts Chemical group 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- KFIKNZBXPKXFTA-UHFFFAOYSA-N dipotassium;dioxido(dioxo)ruthenium Chemical compound [K+].[K+].[O-][Ru]([O-])(=O)=O KFIKNZBXPKXFTA-UHFFFAOYSA-N 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 125000005597 hydrazone group Chemical group 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- 102100024375 Gamma-glutamylaminecyclotransferase Human genes 0.000 description 2
- 101710201613 Gamma-glutamylaminecyclotransferase Proteins 0.000 description 2
- 101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 2
- 101000741797 Homo sapiens Peroxisome proliferator-activated receptor delta Proteins 0.000 description 2
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- TWXHOCQWENATIA-UHFFFAOYSA-N SNNS Chemical compound SNNS TWXHOCQWENATIA-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical group [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000004049 epigenetic modification Effects 0.000 description 2
- 125000001033 ether group Chemical group 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229910052755 nonmetal Inorganic materials 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- HOMROMWVNDUGRI-RVZXSAGBSA-N (2s)-2-aminopentanedioic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O HOMROMWVNDUGRI-RVZXSAGBSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- MJEQLGCFPLHMNV-UHFFFAOYSA-N 4-amino-1-(hydroxymethyl)pyrimidin-2-one Chemical compound NC=1C=CN(CO)C(=O)N=1 MJEQLGCFPLHMNV-UHFFFAOYSA-N 0.000 description 1
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
- NLLCDONDZDHLCI-UHFFFAOYSA-N 6-amino-5-hydroxy-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1O NLLCDONDZDHLCI-UHFFFAOYSA-N 0.000 description 1
- 101000916289 Ctenocephalides felis Salivary antigen 1 Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 101100310856 Drosophila melanogaster spri gene Proteins 0.000 description 1
- 101710198144 Endopolygalacturonase I Proteins 0.000 description 1
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101710191566 Probable endopolygalacturonase I Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241001274197 Scatophagus argus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108010012306 Tn5 transposase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- VJRITMATACIYAF-UHFFFAOYSA-N benzenesulfonohydrazide Chemical compound NNS(=O)(=O)C1=CC=CC=C1 VJRITMATACIYAF-UHFFFAOYSA-N 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910001417 caesium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000003508 chemical denaturation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- JJZAZDAEVNRFGT-MHLYXQECSA-N furaquinocin I Natural products COC1=C(C)C(=O)c2c3O[C@H](C)[C@](C)([C@H](O)CC=C(/C)C(=O)O)c3c(O)cc2C1=O JJZAZDAEVNRFGT-MHLYXQECSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 208000034840 pagnamenta type spondylometaphyseal dysplasia Diseases 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 108700003061 poly(glutamic acid-lysine) Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 229910001419 rubidium ion Inorganic materials 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 108010061905 substance P-saporin Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001847 surface plasmon resonance imaging Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne des procédés de détection de cytosines modifiées dans des séquences d'acides nucléiques.
Applications Claiming Priority (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263269383P | 2022-03-15 | 2022-03-15 | |
| US63/269,383 | 2022-03-15 | ||
| US202263328444P | 2022-04-07 | 2022-04-07 | |
| US63/328,444 | 2022-04-07 | ||
| US202363439501P | 2023-01-17 | 2023-01-17 | |
| US202363439519P | 2023-01-17 | 2023-01-17 | |
| US202363439415P | 2023-01-17 | 2023-01-17 | |
| US202363439443P | 2023-01-17 | 2023-01-17 | |
| US202363439491P | 2023-01-17 | 2023-01-17 | |
| US202363439522P | 2023-01-17 | 2023-01-17 | |
| US202363439466P | 2023-01-17 | 2023-01-17 | |
| US202363439438P | 2023-01-17 | 2023-01-17 | |
| US202363439417P | 2023-01-17 | 2023-01-17 | |
| US63/439,519 | 2023-01-17 | ||
| US63/439,417 | 2023-01-17 | ||
| US63/439,466 | 2023-01-17 | ||
| US63/439,415 | 2023-01-17 | ||
| US63/439,501 | 2023-01-17 | ||
| US63/439,491 | 2023-01-17 | ||
| US63/439,443 | 2023-01-17 | ||
| US63/439,522 | 2023-01-17 | ||
| US63/439,438 | 2023-01-17 | ||
| PCT/EP2023/056668 WO2023175040A2 (fr) | 2022-03-15 | 2023-03-15 | Séquençage simultané de brins complémentaires sens et antisens sur des polynucléotides concaténés pour la détection de méthylation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3223669A1 true CA3223669A1 (fr) | 2023-09-21 |
Family
ID=85800563
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3223669A Pending CA3223669A1 (fr) | 2022-03-15 | 2023-03-15 | Sequencage simultane de brins complementaires sens et antisens sur des polynucleotides concatenes pour la detection de methylation |
| CA3223653A Pending CA3223653A1 (fr) | 2022-03-15 | 2023-03-15 | Sequencage simultane de brins de complement avant et inverse sur des polynucleotides separes pour la detection de methylation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3223653A Pending CA3223653A1 (fr) | 2022-03-15 | 2023-03-15 | Sequencage simultane de brins de complement avant et inverse sur des polynucleotides separes pour la detection de methylation |
Country Status (4)
| Country | Link |
|---|---|
| EP (2) | EP4341425A2 (fr) |
| AU (2) | AU2023233839A1 (fr) |
| CA (2) | CA3223669A1 (fr) |
| WO (2) | WO2023175037A2 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025072783A1 (fr) * | 2023-09-28 | 2025-04-03 | Illumina, Inc. | Cytidine désaminases modifiées et méthodes d'utilisation |
| WO2025096873A1 (fr) * | 2023-10-31 | 2025-05-08 | Ignaty Leshchiner | Séquençage ultra-profond pour identification de dépendances |
| WO2025207886A1 (fr) | 2024-03-28 | 2025-10-02 | Illumina, Inc. | Kits et procédés de préparation de bibliothèque de cuves à circulation et de détection de méthylation |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750341A (en) | 1995-04-17 | 1998-05-12 | Lynx Therapeutics, Inc. | DNA sequencing by parallel oligonucleotide extensions |
| ATE364718T1 (de) | 1997-04-01 | 2007-07-15 | Solexa Ltd | Verfahren zur vervielfältigung von nukleinsäure |
| EP1498494A3 (fr) | 1997-04-01 | 2007-06-20 | Solexa Ltd. | Procédé de séquencage d'acides nucléiques |
| AR021833A1 (es) | 1998-09-30 | 2002-08-07 | Applied Research Systems | Metodos de amplificacion y secuenciacion de acido nucleico |
| AU2001251582A1 (en) | 2000-04-14 | 2001-10-30 | Lynx Therapeutics, Inc. | Method and compositions for ordering restriction fragments |
| US20020012982A1 (en) | 2000-07-13 | 2002-01-31 | Invitrogen Corporation | Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix |
| EP1483404A2 (fr) | 2002-03-05 | 2004-12-08 | Solexa Ltd. | Procedes de detection de variations de sequence a l'echelle du genome associees a un phenotype |
| CA2513535C (fr) * | 2003-01-29 | 2012-06-12 | 454 Corporation | Amplification d'acides nucleiques par emulsion de billes |
| US20050221341A1 (en) * | 2003-10-22 | 2005-10-06 | Shimkets Richard A | Sequence-based karyotyping |
| US20060024681A1 (en) | 2003-10-31 | 2006-02-02 | Agencourt Bioscience Corporation | Methods for producing a paired tag from a nucleic acid sequence and methods of use thereof |
| GB0400584D0 (en) | 2004-01-12 | 2004-02-11 | Solexa Ltd | Nucleic acid chacterisation |
| EP1844162B1 (fr) | 2005-02-01 | 2014-10-15 | Applied Biosystems, LLC | Procédé pour détermine un séquence dans un polynucleotide |
| JP2008538496A (ja) | 2005-04-12 | 2008-10-30 | ４５４ ライフ サイエンシーズ コーポレイション | ウルトラディープ配列決定を用いて配列変異体を決定するための方法 |
| US7601499B2 (en) | 2005-06-06 | 2009-10-13 | 454 Life Sciences Corporation | Paired end sequencing |
| US8428882B2 (en) | 2005-06-14 | 2013-04-23 | Agency For Science, Technology And Research | Method of processing and/or genome mapping of diTag sequences |
| GB0514936D0 (en) | 2005-07-20 | 2005-08-24 | Solexa Ltd | Preparation of templates for nucleic acid sequencing |
| GB0514910D0 (en) | 2005-07-20 | 2005-08-24 | Solexa Ltd | Method for sequencing a polynucleotide template |
| GB0522310D0 (en) | 2005-11-01 | 2005-12-07 | Solexa Ltd | Methods of preparing libraries of template polynucleotides |
| CA2641851A1 (fr) | 2006-02-08 | 2007-08-16 | Eric Hans Vermaas | Procede de sequencage d'une matrice polynucleotidique |
| EP2021503A1 (fr) | 2006-03-17 | 2009-02-11 | Solexa Ltd. | Procédés isothermiques pour créer des réseaux moléculaires clonales simples |
| US7754429B2 (en) | 2006-10-06 | 2010-07-13 | Illumina Cambridge Limited | Method for pair-wise sequencing a plurity of target polynucleotides |
| WO2008093098A2 (fr) | 2007-02-02 | 2008-08-07 | Illumina Cambridge Limited | Procedes pour indexer des echantillons et sequencer de multiples matrices nucleotidiques |
| EP2718465B1 (fr) | 2011-06-09 | 2022-04-13 | Illumina, Inc. | Procede de fabrication d'un reseau d'analytes |
| ES2609845T3 (es) * | 2011-07-29 | 2017-04-24 | Cambridge Epigenetix Limited | Métodos para la detección de modificación de nucleótidos |
| PT3623481T (pt) | 2011-09-23 | 2021-10-15 | Illumina Inc | Composições para sequenciação de ácidos nucleicos |
| WO2013138644A2 (fr) | 2012-03-15 | 2013-09-19 | New England Biolabs, Inc. | Procédés et compositions permettant de distinguer la cytosine de ses variantes et d'analyser le méthylome |
| US8895249B2 (en) | 2012-06-15 | 2014-11-25 | Illumina, Inc. | Kinetic exclusion amplification of nucleic acid libraries |
| CN106103743B (zh) * | 2014-01-07 | 2025-12-02 | Imppc私人基金会 | 用于产生双链dna文库的方法和用于鉴定甲基化胞嘧啶的测序方法 |
| GB201419731D0 (en) * | 2014-11-05 | 2014-12-17 | Illumina Cambridge Ltd | Sequencing from multiple primers to increase data rate and density |
| WO2017075436A1 (fr) | 2015-10-30 | 2017-05-04 | New England Biolabs, Inc. | Compositions et procédés de détermination de cytosines modifiées par séquençage |
| WO2019136376A1 (fr) | 2018-01-08 | 2019-07-11 | Illumina, Inc. | Séquençage à haut débit à détection à semi-conducteur |
| IL296932B1 (en) * | 2018-01-08 | 2025-09-01 | Ludwig Inst For Cancer Res Ltd | Detection of cytosine modifications at base resolution without bisulfite |
| US11359238B2 (en) * | 2020-03-06 | 2022-06-14 | Singular Genomics Systems, Inc. | Linked paired strand sequencing |
| AU2021366658A1 (en) | 2020-10-21 | 2023-06-22 | Illumina Cambridge Limited | Sequencing templates comprising multiple inserts and compositions and methods for improving sequencing throughput |
-
2023
- 2023-03-15 WO PCT/EP2023/056665 patent/WO2023175037A2/fr not_active Ceased
- 2023-03-15 EP EP23714638.6A patent/EP4341425A2/fr active Pending
- 2023-03-15 EP EP23715419.0A patent/EP4341426A2/fr active Pending
- 2023-03-15 WO PCT/EP2023/056668 patent/WO2023175040A2/fr not_active Ceased
- 2023-03-15 CA CA3223669A patent/CA3223669A1/fr active Pending
- 2023-03-15 CA CA3223653A patent/CA3223653A1/fr active Pending
- 2023-03-15 AU AU2023233839A patent/AU2023233839A1/en active Pending
- 2023-03-15 AU AU2023234670A patent/AU2023234670A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4341426A2 (fr) | 2024-03-27 |
| AU2023234670A1 (en) | 2024-01-18 |
| EP4341425A2 (fr) | 2024-03-27 |
| CA3223653A1 (fr) | 2023-09-21 |
| AU2023233839A1 (en) | 2024-01-18 |
| WO2023175037A2 (fr) | 2023-09-21 |
| WO2023175037A3 (fr) | 2023-11-23 |
| WO2023175040A2 (fr) | 2023-09-21 |
| WO2023175040A3 (fr) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3223669A1 (fr) | Sequencage simultane de brins complementaires sens et antisens sur des polynucleotides concatenes pour la detection de methylation | |
| Metzker | Sequencing technologies—the next generation | |
| US9862998B2 (en) | Conformational probes and methods for sequencing nucleic acids | |
| EP2451973B1 (fr) | Procédé de différentiation de brins de polynucléotide | |
| Hutter et al. | Labeled nucleoside triphosphates with reversibly terminating aminoalkoxyl groups | |
| CN115927563A (zh) | 用于分析修饰的核苷酸的组合物和方法 | |
| CA3091335A1 (fr) | Procedes d'analyse epigenetique d'adn, en particulier d'adn acellulaire | |
| JP2019504645A (ja) | 複数のリガーゼ組成物、システム、および方法 | |
| CA3187549A1 (fr) | Compositions et procedes d'analyse d'acides nucleiques | |
| CN114174502B (zh) | 具有改进的引物识别的Phi29 DNA聚合酶突变体 | |
| CN113795591A (zh) | 表征肿瘤并且识别肿瘤异质性的方法和系统 | |
| CN110446791B (zh) | 多核苷酸衔接子及其使用方法 | |
| US20240287578A1 (en) | Concurrent sequencing of forward and reverse complement strands on concatenated polynucleotides for methylation detection | |
| WO2025032340A1 (fr) | Procédé d'amplification d'adn méthylé | |
| EP3673084B1 (fr) | Méthode d'introduction de mutations | |
| US20240301464A1 (en) | Concurrent sequencing of forward and reverse complement strands on separate polynucleotides for methylation detection | |
| WO2024256581A1 (fr) | Identification de cytosines modifiées | |
| WO2025062001A1 (fr) | Séquençage optimisé d'acides nucléiques | |
| US20250043275A1 (en) | Methods of preparing loop fork libraries | |
| WO2025062002A1 (fr) | Séquençage simultané à l'aide d'une traduction de coupure simple brin | |
| WO2024256580A1 (fr) | Séquençage simultané avec des anneaux spatialement séparés | |
| Lo et al. | Mutations altering the interplay between Gk DnaC helicase and DNA reveal an insight into helicase unwinding | |
| JP2003061684A (ja) | Ｄｎａの塩基配列決定法 | |
| Gerrity | Investigations in readlength improvements for DNA sequencing by synthesis | |
| JP2003527119A (ja) | 核酸の差の検出方法 |